SNSE has 36-month beta value of 0.33. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SNSE is 16.30M, and currently, short sellers hold a 0.50% ratio of that float. The average trading volume of SNSE on May 10, 2024 was 173.91K shares.
SNSE) stock’s latest price update
The stock of Sensei Biotherapeutics Inc (NASDAQ: SNSE) has decreased by -14.67 when compared to last closing price of 1.84.Despite this, the company has seen a loss of -4.85% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-09 that BOSTON, April 09, 2024 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA – Better Approaches for Key Targets’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m. ET.
SNSE’s Market Performance
Sensei Biotherapeutics Inc (SNSE) has experienced a -4.85% fall in stock performance for the past week, with a 42.73% rise in the past month, and a 93.83% rise in the past quarter. The volatility ratio for the week is 17.03%, and the volatility levels for the past 30 days are at 14.21% for SNSE. The simple moving average for the past 20 days is 29.45% for SNSE’s stock, with a 77.55% simple moving average for the past 200 days.
Analysts’ Opinion of SNSE
Many brokerage firms have already submitted their reports for SNSE stocks, with Berenberg repeating the rating for SNSE by listing it as a “Hold.” The predicted price for SNSE in the upcoming period, according to Berenberg is $12 based on the research report published on July 01, 2021 of the previous year 2021.
Oppenheimer, on the other hand, stated in their research note that they expect to see SNSE reach a price target of $14, previously predicting the price at $30. The rating they have provided for SNSE stocks is “Perform” according to the report published on June 29th, 2021.
Piper Sandler gave a rating of “Overweight” to SNSE, setting the target price at $25 in the report published on March 01st of the previous year.
SNSE Trading at 44.29% from the 50-Day Moving Average
After a stumble in the market that brought SNSE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.07% of loss for the given period.
Volatility was left at 14.21%, however, over the last 30 days, the volatility rate increased by 17.03%, as shares surge +44.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +86.90% upper at present.
During the last 5 trading sessions, SNSE fell by -4.85%, which changed the moving average for the period of 200-days by +28.69% in comparison to the 20-day moving average, which settled at $1.2368. In addition, Sensei Biotherapeutics Inc saw 126.88% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNSE starting from Celebi John, who purchase 500 shares at the price of $0.85 back on Sep 11 ’23. After this action, Celebi John now owns 111,311 shares of Sensei Biotherapeutics Inc, valued at $425 using the latest closing price.
Apeiron Investment Group Ltd., the 10% Owner of Sensei Biotherapeutics Inc, sale 3,441,661 shares at $1.58 during a trade that took place back on Jun 01 ’23, which means that Apeiron Investment Group Ltd. is holding 0 shares at $5,437,824 based on the most recent closing price.
Stock Fundamentals for SNSE
Current profitability levels for the company are sitting at:
- -13.02 for the present operating margin
- 0.45 for the gross margin
The net margin for Sensei Biotherapeutics Inc stands at -11.55. The total capital return value is set at -0.54. Equity return is now at value -40.52, with -35.38 for asset returns.
Based on Sensei Biotherapeutics Inc (SNSE), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.16. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -257.39.
Currently, EBITDA for the company is -36.49 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 11.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.92.
Conclusion
To put it simply, Sensei Biotherapeutics Inc (SNSE) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
